Coya Therapeutics Extends ALS Trial as Demand for COYA 302 Grows…

Event summary

Coya Therapeutics to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial for COYA 302 in ALS, starting November 2026.
OLE driven by strong interest from investigators and participants to continue treatment beyond the 48-week study period.
Phase 2 trial for COYA 302 in frontotemporal dementia (FTD) delayed to 2027 due to resource prioritization.
Company’s cash runway remains unchanged, expected to fund operations into the second half of 2027.

The big picture

Coya Therapeutics' decision to extend the ALSTARS Trial underscores the critical need for effective ALS treatments, as current therapies only modestly slow disease progression. The shift in resources from FTD to ALS reflects a strategic pivot to prioritize near-term milestones in a high-unmet-need indication. The biotech sector is closely watching how this trial extension and resource reallocation will impact Coya's valuation and competitive positioning in the neurodegenerative disease space.

What we're watching

Trial Success: Whether the open-label extension will provide sufficient long-term efficacy and safety data to support COYA 302's regulatory approval.
Resource Allocation: The impact of delaying the FTD trial on Coya's long-term strategic goals and investor confidence.
Financial Stability: The pace at which Coya can maintain its cash runway while advancing multiple clinical trials.